M&A is an omnipresent reality in the biopharma industry, from Big Pharma mega-mergers to smaller acquisitions of emerging startups.
As it gears up to move its immuno-oncology programs into the clinic, Akrevia Therapeutics has reeled in a $100.5 million series B and changed its name to Xilio Therapeutics to mark its transition from a research-focused company to an R&D-stage one.
My first job at a public company was when I joined Biogen or Biogen Idec as it was then called. One of the rituals of the team was to listen in to the quarterly earnings calls, usually on speaker in a conference room as we drank our morning cup of joe and caught up on emails. It was interesting to hear company leaders describe R&D progress and the quarterly performance figures but the best bit was the incisive analyst questions.
This blog post was written by Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC.
Biotech is in the midst of an incredible era of innovation: new modalities and novel medicines delivering real value to patients, leading to a decade-long bull cycle. It’s been exhilarating to watch and participate in this market, and venture capital activity in biopharma remains near all-time highs.
Cells die all the time in a controlled manner that’s perfectly normal. But the way cells die matters. Sometimes cell death is violent, sparking inflammation believed to contribute to disease. Quench Bio aims to develop drugs that stop the uncontrolled forms of programmed cell death, potentially halting inflammatory disease. The Cambridge, MA-based startup has come out of stealth with $50 million in Series A financing intended to produce a drug candidate ready for tests in humans in about three years.